Forte Biosciences, Inc.

Equities

FBRX

US34962G1094

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 09:47:50 2024-05-16 am EDT			5-day change	1st Jan Change
0.64 ^USD	0.00%		-12.03%	-22.11%

May. 13	Tocagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 18	Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Forte Biosciences, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

August 16, 2021 at 08:46 am EDT

Forte Biosciences, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 5.747 million compared to USD 34.754 million a year ago. Net loss was USD 5.812 million compared to USD 34.761 million a year ago. Basic loss per share from continuing operations was USD 0.43 compared to USD 9.52 a year ago. For the half year, operating loss was USD 10.488 million compared to USD 36.781 million a year ago. Net loss was USD 10.616 million compared to USD 36.811 million a year ago. Basic loss per share from continuing operations was USD 0.79 compared to USD 12.77 a year ago.

Latest news about Forte Biosciences, Inc.

Tocagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Camac Partners Provides Information to Shareholders	Jan. 05	CI
Forte Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Tocagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Forte Biosciences Filed a Motion to Dismiss the Amended Complaint	23-10-28	CI
Camac Fund Files an Amended Class Action and Derivative Complaint	23-10-20	CI
Declaration of Voting Results by Forte Biosciences	23-09-26	CI
Declaration of Voting Results by Forte Biosciences	23-09-26	CI
Declaration of Voting Results by Forte Biosciences	23-09-26	CI
Declaration of Voting Results by Forte Biosciences	23-09-26	CI
Declaration of Voting Results by Forte Biosciences	23-09-20	CI
Forte Biosciences, Inc. Announces Directorate Appointments	23-09-20	CI
Institutional Shareholder Services and Glass Lewis Support Camac Partners	23-09-14	CI
Camac Partners Shares Key Facts that Reinforce the Need for Urgent Change in Forte Biosciences?s Boardroom	23-09-06	CI
Forte Biosciences Issues an Investor Presentation to Shareholders	23-09-01	CI
Camac Partners and ATG Capital Management File Definitive Proxy Statement and Send Letter to Stockholders	23-08-25	CI
Forte Biosciences, Inc Receives Shareholder Proposal from Funicular Funds, LP	23-08-24	CI
Forte Biosciences, Inc Receives Shareholder Proposal from ATG Capital Management LLC	23-08-24	CI
Camac Partners, LLC Files a Definitive Proxy Statement with Securities and Exchange Commission	23-08-24	CI
North American Morning Briefing : China Trouble Hits Sentiment	23-08-18	DJ
Camac Partners, LLC Files a Revised Preliminary Proxy Statement with Securities and Exchange Commission	23-08-17	CI
Forte Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
North American Morning Briefing : Stock Futures -2-	23-08-11	DJ
Funicular Funds Submits a Shareholder Proposal to Forte Biosciences	23-08-02	CI

Chart Forte Biosciences, Inc.

Duration

Period

More charts

Company Profile

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Companyâs FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Companyâs subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.64 USD

Average target price

2.875 USD

Spread / Average Target

+349.22%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
FORTE BIOSCIENCES, INC.	-22.11%	23.29M
VERTEX PHARMACEUTICALS INCORPORATED	+6.56%	113B
REGENERON PHARMACEUTICALS, INC.	+10.96%	106B
ARGENX SE	+0.82%	22.27B
BIONTECH SE	-12.95%	22.22B
GENMAB A/S	-5.89%	19.43B
WUXI APPTEC CO., LTD.	-37.85%	17.87B
BEIGENE, LTD.	-6.92%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.44%	14.29B
SAREPTA THERAPEUTICS, INC.	+34.37%	12.52B

Bio Therapeutic Drugs